Trial Profile

A phase 2b/3 global pivotal study in Prosthetic Joint Infections

Status: Planning

Phase of Trial: Phase II/III

Latest Information Update: 21 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

15 May 2024 According to a PHAXIAM Therapeutics media release, company confirms its objective to file a Clinical Trial Application (CTA) with the EMA and the FDA in 3Q 2024 in view of starting patient enrollment in early 2025. Global Phase 2 study in PJI Regulatory Approval anticipated in 4Q 2024.
15 May 2024 According to a PHAXIAM Therapeutics media release, company is accelerating this PJI clinical development efforts through active preparations of a global Phase 2 proof-of-concept (POC) study and intended to be a multicentric, randomized, double-blind trial and is expected to include 100 patients in Europe and the US. Launch of the global Phase 2 study in PJI anticipated in 1Q 2025.
29 Sep 2023 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com